Imfinzi new dosing approved in the US
20 November 2020 07:00 GMT Imfinzi approved in the US for less-frequent, fixed-dose use Four-week dosing now approved in all Imfinzi indications, reducing medical visits and improving patient convenience AstraZeneca's Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is consistent with the approved Imfinzi dosing in